Analysts at Nomura continue to back Glenmark Pharma, citing the company’s ability to strategically acquire high-potential innovative products.
Why Nomura continues to back Glenmark Pharma; Retains ‘Buy’; Find out here
Analysts at Nomura continue to back Glenmark Pharma, citing the company’s ability to strategically acquire high-potential innovative products.
